VCYT
Veracyte (VCYT)
NASDAQ
$53.80+$0.61 (+1.15%)
Price as of Jun 23, 2026 4:10 PM EDT
  • $4.2B
    Market Cap
  • 99.14%
    1-Year Change
  • Diagnostics & Research
    Industry

Key Performance

More
  • Earnings Score: 45
  • Momentum Score: 99
  • True Yield: N/A
  • Financial Health Score: 100
TradeSmith Loading

Latest Research & News

Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

Healthcare companies are advancing precision medicine through gene therapy, AI diagnostics, and innovative treatments targeting age-related conditions, with several firms making significant breakthroughs in areas like longevity biotechnology and personalized care.

09/25/2025, 9:15 AM • Benzinga

Peers

Statistics

More
Day Range
$52.36
$54.72
$53.19
1-Year Range
$23.03
$53.63
$53.19
Latest Close$53.19
Change
-$0.44 (-0.83%)
Volume967,185
Market Cap$4.2B
Shares Outstanding79.8M
P/E (TTM)48.88
Diluted EPS (TTM)$1.09
Enterprise Value$4.0B

Information as of 06/22/2026

Company Profile

$4.2B
Market Cap
$88.0M
Net Income
Sector: Healthcare
Industry: Diagnostics & Research
6000 Shoreline Court, South San Francisco, CA, United States, 94080
650 243 6300

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Key Executives

  • Marc A. Stapley
  • Phillip G. Febbo
  • Rebecca Chambers
  • John Leite
  • Annie McGuire

Current Ownership Distribution

  • Institutions1.5B (74.48%)
  • Mutual Funds491.5M (25.14%)
  • Insiders7.3M (0.37%)
  • Other0 (0.00%)